UpbeatSix in ten patients responded to a new combination for a brain lymphoma that had come back
Primary central nervous system lymphoma is a rare cancer of the brain and spinal cord, and when it returns after first treatment, options thin quickly. A multicentre Phase 2 trial in China combined two oral and infused medicines — orelabrutinib, which blocks a signal B-cells depend on, and sintilimab, which releases the immune system's brakes. Among 28 patients, 60.7% saw their tumours respond, and responders stayed in response for a median of 42.4 months. Two-year survival stood at 73.3%, with serious side effects in about one in seven patients. The results, published in BMC Cancer, now argue for a larger randomised trial.
The upbeat factorfor a rare cancer with few second chances, a combination that works for most — and lasts for years in those it helps.
SDG 3 · Good health and well-being — Mechanism: tech innovation
Explore:
Healing